Moleculight's proprietary fluorescent imaging platform technology, including the MolecuLight i:X® and DX™ fluorescence imaging systems, provides point-of-care handheld devices for the global wound care market. These devices offer rapid and accurate diagnosis of wounds containing elevated bacterial burden, which cannot be obtained using conventional wound assessment techniques. Founded in 2012 and based in Toronto, Ontario, Moleculight aims to significantly improve outcomes in wound care by leveraging their innovative imaging technology.